Login
$PTN
$6.15 +$0.03 (0.41%) After hours

$PTN 8-K SEC Filings

Filed On Filing
03 Aug 2026 8-K: Submission of Matters to a Vote of Security Holders

On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification of the appointment ...

18 May 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure

PRINCETON, NJ – May 18, 2026 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today ann...

12 Nov 2025 8-K: Other Events

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option

06 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

As Representative of the several Underwriters named on Schedule 1 attached hereto

22 Sep 2025 8-K: Other Events

Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic macular edema

10 Sep 2025 8-K: Other Events

Effective September 10, 2025, the Company’s common stock began trading on the OTCQB Market of the OTC Market Group under the symbol “PTNT”, reflecting the expiration of the twenty trading day period under the symbol “PTNTD” following the...

18 Aug 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

08 Aug 2025 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Palatin Technologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify:

29 Jul 2025 8-K: Submission of Matters to a Vote of Security Holders

On July 25, 2025, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) an amendment to the Company’s Re...

09 Jul 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 7, 2025, Palatin Technologies, Inc. (the “Company”) received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that a Listing Qualifications Panel (the “Panel”) of the Exchange’s Committee fo...

13 Jun 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ...

08 May 2025 8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule +1 more

This Securities Purchase Agreement (this “Agreement”) is dated as of May 7, 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it...

10 Apr 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events

CRANBURY, NJ – April 10, 2025/PRNewswire/ – Palatin Technologies, Inc. (the “Company”) (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin...

31 Mar 2025 8-K: Other Events

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment.

12 Feb 2025 8-K: Entry into a Material Definitive Agreement

Palatin Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows:

10 Feb 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This Securities Purchase Agreement (this “Agreement”) is dated as of February 6, 2025 between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, includin...

16 Dec 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION U...

14 Nov 2024 8-K: Results of Operations and Financial Condition

Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates

07 Oct 2024 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events

CRANBURY, NJ – October 7, 2024 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor sys...

01 Oct 2024 8-K: Results of Operations and Financial Condition

Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support